SBIR-STTR Award

SUMMARY The Covid-19 pandemic caused by Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) is currentlythe most important public health crisis in the world. Given the unprecedented scope of this disease, it is criticalto explore novel strategies to mitigate this crisis. Aleph Therapeutics and UCSF have jointly developed eTIP1,a Therapeutic Interfering Particle. eTIP1 was developed under a DARPA-funded program and shows potentbroad-spectrum activity across enteroviruses (Poliovirus Type 1 and 3, EVA71, and Coxsackievirus B3) as wellas respiratory viruses EV-D68/HRV-87, Rhinovirus A16 and A1B, and Influenza A. Recently we have shownthat eTIP1 significantly inhibits replication of SARS-CoV-2 both in cell culture and in K18-ACE2 mice. Giventhese results, it is critical to thoroughly evaluate eTIP1 as a potential agent against SARS-CoV-2. This workcould be the starting point for a potential therapy or prophylactic agent against SARS-CoV-2. This would alsorepresent a significant breakthrough for the development of a broad-spectrum antiviral agent that couldpotentially target current and future viral threats. NARRATIVE The Covid-19 pandemic caused by Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) is currently the most important public health crisis in the world. Aleph Therapeutics and UCSF have jointly developed eTIP1, a Therapeutic Interfering Particle, that shows potent broad-spectrum activity against several respiratory viruses. Preliminary results indicate that eTIP1 significantly inhibits replication of SARS-CoV-2 both in cell culture and in K18-ACE2 mice and the goal of this proposal is to thoroughly evaluate eTIP1 as a potential agent against SARS-CoV-2. Alpha Particles ; Alpha Particle Radiation ; Alpha Radiation ; α Particles ; Antiviral Agents ; Antiviral Drugs ; Antivirals ; anti-viral agents ; anti-viral drugs ; anti-virals ; Body Weight ; Brunhilde Virus ; Poliovirus Type 1 ; Cell Culture Techniques ; cell culture ; Cells ; Cell Body ; Clinical Markers ; Coxsackie Viruses ; Coxsackievirus ; Disease ; Disorder ; Enterovirus ; Epithelial Cells ; Future ; Goals ; Infection ; Lung ; Lung Respiratory System ; pulmonary ; Lung diseases ; Pulmonary Diseases ; Pulmonary Disorder ; Respiratory Disease ; Respiratory System Disease ; Respiratory System Disorder ; disease of the lung ; disorder of the lung ; lung disorder ; Transgenic Mice ; Mus ; Mice ; Mice Mammals ; Murine ; Organoids ; Production ; Public Health ; Rhinovirus ; RNA ; Non-Polyadenylated RNA ; RNA Gene Products ; Ribonucleic Acid ; Messenger RNA ; mRNA ; Safety ; Drug or chemical Tissue Distribution ; Tissue Distribution ; Virus ; Work ; K-18 conjugate ; K-18 ; K18 ; K18 combination ; Measures ; base ; Acute ; Clinical ; Animal Experiments ; Coronavirus ; Coronaviridae ; corona virus ; Structure of respiratory epithelium ; Respiratory Epithelium ; Funding ; Immunological response ; host response ; immune system response ; immunoresponse ; Immune response ; Therapeutic ; programs ; prophylactic ; Viral ; respiratory ; particle ; respiratory virus ; Animal Models and Related Studies ; model of animal ; model organism ; Animal Model ; Toxicities ; Toxic effect ; Influenza A ; Influenza Viruses Type A ; Influenzavirus A ; Orthomyxovirus Type A ; Type A Influenza ; Influenza A virus ; preventing ; prevent ; Data ; Monitor ; Process ; Development ; developmental ; efficacy evaluation ; efficacy analysis ; efficacy assessment ; efficacy examination ; evaluate efficacy ; examine efficacy ; novel strategies ; new approaches ; novel approaches ; novel strategy ; novel therapeutics ; new drug treatments ; new drugs ; new therapeutics ; new therapy ; next generation therapeutics ; novel drug treatments ; novel drugs ; novel therapy ; mouse model ; murine model ; A549 ; treatment response ; response to treatment ; therapeutic response ; efficacy testing ; experimental study ; experiment ; experimental research ; Innate Immune Response ; lipid nanoparticle ; COVID-19 ; COVID19 ; CV-19 ; CV19 ; corona virus disease 2019 ; coronavirus disease 2019 ; 2019-nCoV ; 2019 novel corona virus ; 2019 novel coronavirus ; COVID-19 virus ; COVID19 virus ; CoV-2 ; CoV2 ; SARS corona virus 2 ; SARS-CoV-2 ; SARS-CoV2 ; SARS-associated corona virus 2 ; SARS-associated coronavirus 2 ; SARS-coronavirus-2 ; SARS-related corona virus 2 ; SARS-related coronavirus 2 ; SARSCoV2 ; Severe Acute Respiratory Distress Syndrome CoV 2 ; Severe Acute Respiratory Distress Syndrome Corona Virus 2 ; Severe Acute Respiratory Distress Syndrome Coronavirus 2 ; Severe Acute Respiratory Syndrome CoV 2 ; Severe Acute Respiratory Syndrome-associated coronavirus 2 ; Severe Acute Respiratory Syndrome-related coronavirus 2 ; Severe acute respiratory syndrome associated corona virus 2 ; Severe acute respiratory syndrome corona virus 2 ; Severe acute respiratory syndrome coronavirus 2 ; Severe acute respiratory syndrome related corona virus 2 ; Wuhan coronavirus ; coronavirus disease 2019 virus ; hCoV19 ; nCoV2 ; COVID-19 pandemic ; COVID crisis ; COVID epidemic ; COVID pandemic ; COVID-19 crisis ; COVID-19 epidemic ; COVID-19 global health crisis ; COVID-19 global pandemic ; COVID-19 health crisis ; COVID-19 public health crisis ; COVID19 crisis ; COVID19 epidemic ; COVID19 global health crisis ; COVID19 global pandemic ; COVID19 health crisis ; COVID19 pandemic ; COVID19 public health crisis ; SARS-CoV-2 epidemic ; SARS-CoV-2 global health crisis ; SARS-CoV-2 global pandemic ; SARS-CoV-2 pandemic ; SARS-CoV2 epidemic ; SARS-CoV2 pandemic ; SARS-coronavirus-2 epidemic ; SARS-coronavirus-2 pandemic ; Severe Acute Respiratory Syndrome CoV 2 epidemic ; Severe Acute Respiratory Syndrome CoV 2 pandemic ; Severe acute respiratory syndrome coronavirus 2 epidemic ; Severe acute respiratory syndrome coronavirus 2 pandemic ; corona virus disease 2019 epidemic ; corona virus disease 2019 pandemic ; coronavirus disease 2019 crisis ; coronavirus disease 2019 epidemic ; coronavirus disease 2019 global health crisis ; coronavirus disease 2019 global pandemic ; coronavirus disease 2019 health crisis ; coronavirus disease 2019 pandemic ; coronavirus disease 2019 public health crisis ; coronavirus disease crisis ; coronavirus disease epidemic ; coronavirus disease pandemic ; severe acute respiratory syndrome coronavirus 2 global health crisis ; severe acute respiratory syndrome coronavirus 2 global pandemic ; ACE2 ; angiotensin converting enzyme 2 ; angiotensin converting enzyme II ;

The Covid-19 pandemic caused by Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) is currentlythe most important public health crisis in the world. Given the unprecedented scope of this disease, it is criticalto explore novel strategies to mitigate this crisis. Aleph Therapeutics and UCSF have jointly developed eTIP1,a Therapeutic Interfering Particle. eTIP1 was developed under a DARPA-funded program and shows potentbroad-spectrum activity across enteroviruses (Poliovirus Type 1 and 3, EVA71, and Coxsackievirus B3) as wellas respiratory viruses EV-D68/HRV-87, Rhinovirus A16 and A1B, and Influenza A. Recently we have shownthat eTIP1 significantly inhibits replication of SARS-CoV-2 both in cell culture and in K18-ACE2 mice. Giventhese results, it is critical to thoroughly evaluate eTIP1 as a potential agent against SARS-CoV-2. This workcould be the starting point for a potential therapy or prophylactic agent against SARS-CoV-2. This would alsorepresent a significant breakthrough for the development of a broad-spectrum antiviral agent that couldpotentially target current and future viral threats.

Public Health Relevance Statement:
NARRATIVE The Covid-19 pandemic caused by Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) is currently the most important public health crisis in the world. Aleph Therapeutics and UCSF have jointly developed eTIP1, a Therapeutic Interfering Particle, that shows potent broad-spectrum activity against several respiratory viruses. Preliminary results indicate that eTIP1 significantly inhibits replication of SARS-CoV-2 both in cell culture and in K18-ACE2 mice and the goal of this proposal is to thoroughly evaluate eTIP1 as a potential agent against SARS-CoV-2.

Project Terms:
<α Particles><2019-nCoV><2019 novel corona virus><2019 novel coronavirus>